Trial Profile
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL PF-04136309 500 MG BID IN SUBJECTS WITH CHRONIC HCV INFECTION AND RAISED AMINOTRANSFERASES
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 31 Jul 2023
Price :
$35
*
At a glance
- Drugs PF 4136309 (Primary)
- Indications Hepatitis C
- Focus Biomarker; Therapeutic Use
- 19 Mar 2012 Actual patient number changed from 21 to 24 as reported by ClinicalTrials.gov.
- 19 Mar 2012 Actual end date (1 Feb 2012) added as reported by ClinicalTrials.gov.
- 19 Mar 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.